Skip to main content
Equibles
CYH logo

CYH · Community Health Systems Inc · Metrics

Track CYH — free

Use CYH with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CYH.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.39 -0.45 (-15.85%) Q2 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$400.47M
Shares
141.01M
Volume · Oct 28 2.06M Avg daily vol (3M) 1.2M

CYH metrics

105 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$2.66
Market cap
$400.47M

Price action

20 metrics
Price change (1W)
-0.4%
Price change (30D)
-1.7%
Price change (3M)
+1.8%
Price change (6M)
-1.4%
Price change (YTD)
-9.0%
Price change (1Y)
-35.6%
Trailing year
Price change (5Y)
-71.9%
52-week high
$4.41
52-week low
$2.49
Change from 52-week high
-35.6%
Change from 52-week low
+14.1%
Annualized volatility
49.7%
Annualized volatility (3M)
34.4%
Beta
0.9
RSI (14D)
47.4
Price vs SMA 50
-2.0%
Price vs SMA 200
-6.7%
Avg volume (3M)
1.21M
Relative volume
1.6
Average dollar volume
$3.50M

Company

3 metrics
Sector
Healthcare
Industry
Medical Care Facilities
Shares outstanding
141.01M

Valuation

12 metrics
P / E (TTM)
1.5
Trailing earnings · reciprocal yield 65.5%
PEG ratio
—
EV / revenue
0.8×
reciprocal yield 121.9%
EV / EBITDA
5.5×
reciprocal yield 18.3%
EV / EBIT
7.2×
reciprocal yield 13.9%
P / sales
0.0×
reciprocal yield 2,992.3%
P / book
—
FCF yield
-46.2%
TTM · current market cap
Buyback yield
6.7%
P / FCF
—
P / operating cash flow
3.2
reciprocal yield 31.5%
Earnings yield
62.9%

Historical valuation

8 metrics
P / E historical average (3Y)
1.4×
reciprocal yield 70.9%
P / E historical average (5Y)
4.6×
reciprocal yield 22.0%
EV / revenue historical average (3Y)
0.9×
reciprocal yield 109.9%
EV / revenue historical average (5Y)
0.9×
reciprocal yield 105.3%
EV / EBIT historical average (3Y)
12.9×
reciprocal yield 7.7%
EV / EBIT historical average (5Y)
12.3×
reciprocal yield 8.1%
EV / EBITDA historical average (3Y)
8.2×
reciprocal yield 12.3%
EV / EBITDA historical average (5Y)
7.9×
reciprocal yield 12.6%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
6.7%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-10-29
Last earnings
2026-07-23

Profitability

9 metrics
Gross margin
85.4%
Operating margin
11.4%
Trailing 12 months
Net margin
2.1%
Gross profit (TTM)
$10.23B
Operating profit (TTM)
$1.36B
Net income (TTM)
$252.00M
Trailing 12 months
Diluted EPS (TTM)
$1.86
FCF margin
-1.5%
Effective tax rate
11.4%

Per share

11 metrics
Revenue per diluted share (TTM)
$88.25
Gross profit per diluted share (TTM)
$75.38
Operating profit per diluted share (TTM)
$10.01
EBITDA per diluted share (TTM)
$13.24
Net income per diluted share (TTM)
$1.85
Operating cash flow per diluted share (TTM)
$0.89
Free cash flow per diluted share (TTM)
$-1.40
Capital expenditures per diluted share (TTM)
$2.29
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
$0.07
Book value per share
$-10.06

Growth

11 metrics
Revenue growth YoY
-9.8%
Year over year
Net income growth YoY
-75.2%
Revenue (TTM)
$11.98B
Trailing 12 months
EPS growth YoY
-75.6%
Shares change YoY
+1.2%
Year over year · more shares
Revenue CAGR (3Y)
+0.7%
Revenue CAGR (5Y)
+1.2%
EPS CAGR (3Y)
+120.8%
EPS CAGR (5Y)
-3.0%
FCF CAGR (3Y)
—
FCF CAGR (5Y)
-34.6%

Quality

14 metrics
Return on equity
—
Return on assets
2.1%
Debt / equity
—
Current ratio
1.5
EBITDA (TTM)
$1.80B
Free cash flow (TTM)
−$185.00M
Quick ratio
1.5
Interest coverage
1.6
Net debt / EBITDA
5.2
Return on invested capital
15.0%
Trailing 12 months
Net cash
−$9.43B
Latest balance sheet
Cash & equivalents
$149.00M
Total assets
$12.18B
Total debt
$9.58B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$126.00M
Capital expenditures (TTM)
$311.00M
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
$9.00M
R&D / revenue
—
Stock compensation / revenue
0.1%

Ownership (13F)

9 metrics
13F filers
183
13F filer change QoQ
+5
Institutional ownership
83.0%
Conviction holders (share of 13F filers)
1.7%
Crowding (high-turnover and private-fund holders)
36.9%
Private-fund adviser ownership
33.9%
Active holders' share change QoQ
+8.6%
Holder tenure
14.2
Price vs estimated holder cost
-0.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
13.8%

Short interest

3 metrics
Short interest
8.7%
Latest settlement · 11.3 days to cover
Days to cover
11.3d
Short-squeeze score
77 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$118,400
Insider-sentiment score
44 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1108109 CUSIP 203668108 13F (30d) 27 filings 27 filers Visit website Investor relations